04:11 PM EST, 11/12/2025 (MT Newswires) -- Celcuity ( CELC ) reported a Q3 adjusted loss late Wednesday of $0.78 per diluted share, wider than a loss of $0.65 a year earlier.
Three analysts expected a loss of $0.96 in a FactSet poll.
The clinical-stage biotechnology company said it has funds to run its operations through 2027.